KDIGO 2024 Chronic Kidney Disease Guideline: Precision CKD Care for Pharmacists

The 2024 KDIGO guideline for CKD introduces new recommendations for screening, diagnosis, risk stratification, pharmacologic intervention, and bone-mineral disorder, with significant implications for pharmacist monitoring roles.

KDIGO guidelineKDIGO 2024chronic kidney diseaseSGLT2 inhibitorsRAAS inhibitorsnsMRAmineral bone disorderrenal drug dosing Chronic Kidney Disease

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group

Citation: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →